Abstract: Compositions are provided comprising a macrolide T-cell immunomodulator or immunosuppressant agent, e.g. pimecrolimus, and at least one anti-photoaging agent such as a sunscreen, an anti-oxidant or a DNA-repair enzyme. They are useful in particular in the curative treatment or prevention of dermatological diseases and of conditions where it is desired to inhibit the skin aging effects of light radiation such as UV-A and UV-B light, e.g. development of skin cancer.

Abstract: Synergistic combinations of a macrolide T-cell immunomodulator or immunosuppressant such as 33-epichloro-33-desoxyascomycin and an emollient such as dimethicone, glycerol or isostearyl isostearate are provided, which are useful in particular in the treatment of dermatological or mucosal diseases such as dry skin or atopic or contact dermatitis.

Abstract: Highly compatible or synergistic combinations of a macrolide T-cell immunomodulator or immunosuppressant such as 33-epichloro-33-desoxyascomycin and an antibacterial such as sulfasalazin, ciprofloxacin, ofloxacin, erythromycin or gentamycin, optionally with a further pharmaceutically active agent, especially a retinoid, are provided, which are useful in particular in the treatment of diseases involving bacterial or suspected or anticipated bacterial infection, for immunomodulation or immunosuppression in conditions in which bacterial or suspected or anticipated bacterial colonization of e.g. the skin plays a role, such as atopic, contact and seborrhoeic dermatitis, eczema, psoriasis, acne, rosacea, post-peel, skin burning, itching, or IBD, and in situations of bacterial resistance.

Abstract: Synergistic combinations of a macrolide T-cell immunomodulator or immunosuppressant such as 33-epichloro-33-desoxyascomycin and a calciferol or tacalcitol are provided, which are useful in particular in the treatment of dermatological diseases such as atopic dermatitis, acen and psoriasis or of inflammatory bowel disease (IBD).

Abstract: Additive or synergistic combinations of a macrolide T-cell immunomodulator or immunosuppressant such as 33-epichloro-33-desoxyascomycin and a retinoid, such as etretinate, isotretinoin or tazarotene, optionally with a further pharmaceutically active agent, especially an antibacterial, are provided, which are useful in particular in the treatment of dermatological diseases such as eczema, atopic dermatitis, acne, psoriasis, skin aging, sun damage, post-peel erythema and stretch marks.

Abstract: The present invention relates to sustained release pharmaceutical composition for oral administration comprising terbinafine.